Intelligent Bio Solutions (INBS) Announces Proposed Public Offering

Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing and delivering intelligent, non-invasive, real-time testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All of the securities are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager for the offering.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission (“SEC”) on April 8, 2022, and declared effective by the SEC on April 20, 2022.

You May Also Be Interested In

• Streamex's GLDY token available via Siebert brokerage accounts
• Neurogene reports Phase 1/2 gene therapy data for Rett syndrome
• Zymeworks to acquire Theravance Biopharma for $17 per share